echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > New migraine medicine! Lingbei CGRP targeted antibody Vyepti entered the EU review: the first day of effective, 4 times a year intravenous dosing!

    New migraine medicine! Lingbei CGRP targeted antibody Vyepti entered the EU review: the first day of effective, 4 times a year intravenous dosing!

    • Last Update: 2021-01-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.